A systematic review and meta-analysis of visuospatial attentional deficits in Parkinson's patients.

Neurosci Biobehav RevJul 23, 2026 (epub)
Clinical ResearchNeurology

Madalina Bucur, Alexandria N Holcomb, Maurizio Luciani et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis investigated visuospatial attentional deficits in right-handed, cognitively unimpaired patients with Parkinson's disease (PD). The analysis of 51 studies revealed that PD patients exhibited significant impairments in sustained, selective, and divided attention, particularly in exogenous orienting, while alerting and endogenous orienting remained intact. The findings underscore the cognitive challenges faced by PD patients, especially under demanding conditions.

Key findings

  • PD patients showed deficits in sustained, selective, and divided attention.
  • Only exogenous orienting was impaired, while alerting and endogenous orienting were preserved.
  • Visuospatial bias indicated small, context-dependent shifts in spatial attention.
  • Right-predominant motor symptoms were associated with subtle rightward spatial tendencies.

Why it matters

Understanding attentional deficits in Parkinson's disease is crucial for clinicians as it informs cognitive assessments and rehabilitation strategies, ultimately enhancing patient care and management.

Source

Published in Neurosci Biobehav Rev. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.